QYUNS-B (02509) spent 1.835 million Hong Kong dollars to repurchase 84,000 shares on January 20th.
Chun Sing Biology-B (02509) announced that it repurchased 84,000 shares at a cost of HK$1.835 million on January 20, 2026.
QYUNS-B (02509) announced on January 20, 2026 that it would spend 1.835 million Hong Kong dollars to repurchase 84,000 shares.
Related Articles
KOS INTL (08042) is planning to change its name to "KOS INTL Talent Group Limited Company".
EXTRAWELL PHAR(00858): Yang Xiaorong appointed as an independent non-executive director.
GlaxoSmithKline plc Sponsored ADR (GSK.US) acquired RAPT Therapeutics (RAPT.US) for a valuation of $2.2 billion, causing a significant increase in pre-market trading.
KOS INTL (08042) is planning to change its name to "KOS INTL Talent Group Limited Company".
EXTRAWELL PHAR(00858): Yang Xiaorong appointed as an independent non-executive director.
GlaxoSmithKline plc Sponsored ADR (GSK.US) acquired RAPT Therapeutics (RAPT.US) for a valuation of $2.2 billion, causing a significant increase in pre-market trading.
